Novo Nordisk A S (NONOF) — 6-K Filings

All 6-K filings from Novo Nordisk A S. Browse 49 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (49)

6-K Filing — Dec 23, 2025
Novo Nordisk's Amycretin Shows Strong Weight Loss in Diabetes Trial — Nov 25, 2025 Risk: medium
Novo Nordisk A/S announced on November 25, 2025, positive results from a Phase 2 trial of its drug amycretin for type 2 diabetes. The trial showed statistically
Novo Nordisk Alzheimer's Trials Fail to Meet Primary Endpoint — Nov 24, 2025 Risk: high
Novo Nordisk announced on November 24, 2025, that its Phase 3 Evoke and Evoke+ trials for an Alzheimer's disease treatment did not show a statistically signific
Novo Nordisk Discloses Insider Share Transactions — Nov 17, 2025 Risk: low
On November 17, 2025, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordan
6-K Filing — Nov 14, 2025
6-K Filing — Nov 12, 2025
Novo Nordisk to Lower GLP-1 Prices for US Medicare — Nov 7, 2025 Risk: medium
Novo Nordisk announced on November 6, 2025, an agreement with the U.S. Administration to expand access to its GLP-1 obesity medicines for more Americans at a lo
6-K Filing — Nov 5, 2025
Novo Nordisk proposes Metsera acquisition — Oct 30, 2025 Risk: medium
On October 30, 2025, Novo Nordisk A/S submitted an unsolicited proposal to acquire Metsera, Inc. This potential acquisition includes Metsera's early and develop
Novo Nordisk Calls EGM for Board Elections — Oct 21, 2025 Risk: low
Novo Nordisk A/S announced on October 21, 2025, that its Board of Directors has decided to convene an Extraordinary General Meeting. The purpose of this meeting
Novo Nordisk to Acquire Akero Therapeutics for MASH Portfolio — Oct 9, 2025 Risk: medium
On October 9, 2025, Novo Nordisk A/S announced its intention to acquire Akero Therapeutics for an undisclosed amount. This acquisition aims to bolster Novo Nord
Novo Nordisk to cut 9,000 jobs for growth reinvestment — Sep 10, 2025 Risk: medium
Novo Nordisk A/S announced on September 10, 2025, a plan to streamline operations and reinvest for growth, particularly in diabetes and obesity. This transforma
Novo Nordisk Discloses Insider Trading Activity — Aug 19, 2025 Risk: low
On August 19, 2025, Novo Nordisk A/S filed a Form 6-K to report transactions in its shares by board members, executives, and associated persons. This disclosure
Novo Nordisk's Wegovy Approved for MASH in US — Aug 18, 2025 Risk: low
On August 15, 2025, Novo Nordisk announced that the US Food and Drug Administration (FDA) approved an additional indication for Wegovy® (semaglutide 2.4 mg). Th
Novo Nordisk Discloses Insider Share Transactions — Aug 14, 2025 Risk: low
Novo Nordisk A/S announced on August 12, 2025, that it is disclosing transactions in its shares made by board members, executives, and associated persons. This
Novo Nordisk Discloses Insider Share Transactions — Aug 8, 2025 Risk: low
On August 7, 2025, Novo Nordisk A/S disclosed transactions in its own shares by board members, executives, and associated persons. This disclosure is in accorda
Novo Nordisk Files Routine 6-K Report — Aug 6, 2025 Risk: low
Novo Nordisk A/S filed a Form 6-K on August 6, 2025, reporting its financial information as of June 30, 2025. The filing is a routine report for foreign private
Novo Nordisk Responds to TRC Capital Mini-Tender Offer — Aug 4, 2025 Risk: medium
On August 4, 2025, Novo Nordisk A/S announced it has received notice of an unsolicited "mini-tender" offer from TRC Capital Investment Corporation. TRC Capital
Novo Nordisk Lowers 2025 Outlook Despite Strong H1 Growth — Jul 29, 2025 Risk: medium
Novo Nordisk announced on July 29, 2025, that its sales increased by 18% and operating profit grew in the first six months of 2025. However, the company has low
Novo Nordisk Advances Amycretin to Phase 3 for Weight Management — Jun 13, 2025 Risk: low
Novo Nordisk announced on June 12, 2025, that it will advance both subcutaneous and oral formulations of amycretin into Phase 3 clinical development for weight
Novo Nordisk CEO Lars Fruergaard Jørgensen to Step Down — May 16, 2025 Risk: medium
Novo Nordisk announced on May 16, 2025, that CEO Lars Fruergaard Jørgensen will step down as CEO by mutual agreement with the Board. He will continue in his rol
Novo Nordisk Discloses Insider Share Transactions — May 9, 2025 Risk: low
On May 9, 2025, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordance wit
Novo Nordisk Files Q1 2025 Report — May 7, 2025 Risk: low
Novo Nordisk A/S filed a Form 6-K on May 7, 2025, reporting its first quarter results for the period ending March 31, 2025. The company, headquartered in Bagsva
Novo Nordisk Executive VP Camilla Sylvest Departs — Apr 3, 2025 Risk: low
Novo Nordisk A/S announced on April 3, 2025, that Camilla Sylvest will be leaving the company after 28 years, including seven years as executive vice president
Novo Nordisk Reports Strong 2024 Growth at AGM — Mar 31, 2025 Risk: low
Novo Nordisk A/S held its Annual General Meeting on March 27, 2025, where Helge Lund, chair of the Board of Directors, reported that 2024 was a year of signific
Novo Nordisk's CagriSema Shows Superior Weight Loss in Phase 3 Trial — Mar 10, 2025 Risk: low
Novo Nordisk announced positive headline results from its Phase 3 REDEFINE 2 trial on March 10, 2025. The trial investigated the efficacy and safety of once-wee
Novo Nordisk Annual General Meeting Set for March 27 — Feb 27, 2025 Risk: low
Novo Nordisk A/S announced its Annual General Meeting will be held on March 27, 2024, at 2:00 PM CET at Bella Center. The meeting will be partially electronic,
Novo Nordisk Discloses Insider Trading Activity — Feb 7, 2025 Risk: low
On February 7, 2025, Novo Nordisk A/S filed a Form 6-K to report transactions in its shares by board members, executives, and associated persons. This disclosur
Novo Nordisk Discloses Insider Share Transactions — Feb 6, 2025 Risk: low
On February 6, 2025, Novo Nordisk A/S disclosed transactions in its own shares by board members, executives, and associated persons. This disclosure is made in
Novo Nordisk Initiates Share Repurchase Program — Feb 4, 2025 Risk: low
Novo Nordisk A/S announced on February 4, 2025, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance
Novo Nordisk Initiates Share Repurchase Program — Jan 27, 2025 Risk: low
Novo Nordisk A/S announced on January 27, 2025, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance
Novo Nordisk Obesity Drug Amycretin Shows Promise in Trial — Jan 24, 2025 Risk: medium
Novo Nordisk A/S announced positive topline results on January 24, 2025, from a Phase 1b/2a clinical trial for its subcutaneous amycretin drug. Amycretin is des
Novo Nordisk Completes Share Repurchase Program — Jan 21, 2025 Risk: low
Novo Nordisk A/S announced on January 20, 2025, that it has completed a share repurchase program initiated on November 11, 2024. The company repurchased a total
Novo Nordisk Semaglutide Shows Strong Weight Loss in Obesity Trial — Jan 17, 2025 Risk: low
Novo Nordisk announced headline results from its Phase 3b STEP UP trial on January 17, 2025. The trial investigated subcutaneous semaglutide 7.2 mg for obesity
Novo Nordisk Completes DKK 1B Share Repurchase — Jan 15, 2025 Risk: low
Novo Nordisk A/S announced on January 13, 2025, that it has completed its share repurchase program initiated on November 11, 2024. The company repurchased a tot
Novo Nordisk's CagriSema Shows Superior Weight Loss in Obesity Trial — Dec 20, 2024 Risk: low
Novo Nordisk announced positive headline results from its Phase 3 REDEFINE 1 trial on December 20, 2024. The trial investigated CagriSema, a fixed-dose combinat
Novo Nordisk Completes Acquisition of 3 Manufacturing Sites — Dec 18, 2024 Risk: low
Novo Nordisk announced on December 18, 2024, the completion of its acquisition of three manufacturing sites from Novo Holdings A/S. This acquisition is a conseq
Novo Nordisk Catalent Acquisition Cleared to Close — Dec 16, 2024 Risk: low
Novo Nordisk A/S announced on December 14, 2024, that the acquisition of Catalent, Inc. by Novo Holdings A/S has received all necessary regulatory approvals. As
EMA backs Ozempic label update for kidney risk reduction — Dec 13, 2024 Risk: low
On December 12, 2024, Novo Nordisk announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive
Novo Nordisk Initiates Share Repurchase Program — Dec 9, 2024 Risk: low
On December 9, 2024, Novo Nordisk A/S announced the initiation of a share repurchase program. This program is being conducted in accordance with European regula
EU Approves Novo Holdings' Catalent Acquisition — Dec 6, 2024 Risk: low
On December 6, 2024, the European Commission approved Novo Holdings A/S' acquisition of Catalent, Inc. This approval is a key step for Novo Nordisk's subsequent
Novo Nordisk Initiates Share Repurchase Program — Dec 2, 2024 Risk: low
Novo Nordisk A/S announced on December 2, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordance
Novo Nordisk Launches Share Repurchase Program — Nov 25, 2024 Risk: low
Novo Nordisk A/S announced on November 25, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordanc
Novo Nordisk Reports Insider Share Transactions — Nov 19, 2024 Risk: low
Novo Nordisk A/S filed a Form 6-K on November 19, 2024, to report transactions in its shares by board members, executives, and associated persons. This disclosu
Novo Nordisk Initiates Share Repurchase Program — Nov 18, 2024 Risk: low
Novo Nordisk A/S announced on November 18, 2024, that it initiated a share repurchase program on November 11, 2024. This program is being conducted in accordanc
Novo Nordisk Discloses Insider Share Transactions — Nov 14, 2024 Risk: low
On November 13, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is in accordan
Novo Nordisk Discloses Insider Share Transactions — Nov 13, 2024 Risk: low
Novo Nordisk A/S filed a Form 6-K on November 13, 2024, reporting transactions in its shares by board members, executives, and associated persons. This disclosu
Novo Nordisk Discloses Insider Trading Activity — Nov 8, 2024 Risk: low
On November 8, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This disclosure is made in acco
Novo Nordisk Discloses Insider Share Transactions — Nov 7, 2024 Risk: low
On November 7, 2024, Novo Nordisk A/S disclosed transactions in its shares by board members, executives, and associated persons. This report, filed under Form 6

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX